Total Payments
$1.4M
2024 Payments
$316,391
Companies
44
Transactions
1,968
Medicare Patients
8,946
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$1.2M (85.1%)
Travel$134,483 (9.4%)
Consulting$47,553 (3.3%)
Food & Beverage$31,047 (2.2%)
Education$565.57 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 423 | 85.1% |
| Travel and Lodging | $134,483 | 561 | 9.4% |
| Consulting Fee | $47,553 | 17 | 3.3% |
| Food and Beverage | $31,047 | 960 | 2.2% |
| Education | $565.57 | 7 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $530,153 | 522 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $384,447 | 489 | $0 (2024) |
| GlaxoSmithKline, LLC. | $206,349 | 344 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $83,636 | 141 | $0 (2019) |
| Bayer Healthcare Pharmaceuticals Inc. | $75,703 | 95 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $48,802 | 81 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $44,587 | 62 | $0 (2024) |
| Merck Sharp & Dohme LLC | $19,862 | 21 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $14,475 | 39 | $0 (2019) |
| Gilead Sciences Inc | $14,459 | 20 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $316,391 | 389 | AstraZeneca Pharmaceuticals LP ($129,985) |
| 2023 | $193,092 | 264 | Actelion Pharmaceuticals US, Inc. ($97,854) |
| 2022 | $193,664 | 234 | AstraZeneca Pharmaceuticals LP ($119,988) |
| 2021 | $184,544 | 211 | AstraZeneca Pharmaceuticals LP ($79,526) |
| 2020 | $75,726 | 114 | GlaxoSmithKline, LLC. ($36,656) |
| 2019 | $129,993 | 219 | Actelion Pharmaceuticals US, Inc. ($49,671) |
| 2018 | $136,585 | 229 | Actelion Pharmaceuticals US, Inc. ($63,001) |
| 2017 | $200,561 | 308 | Actelion Pharmaceuticals US, Inc. ($108,176) |
All Payment Transactions
1,968 individual payment records from CMS Open Payments — Page 1 of 79
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Vifor Pharma, Inc. | Zemaira (Drug) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 12/12/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $30.37 | General |
| Category: Cardiology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $24.69 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/10/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: Pulmonology | ||||||
| 12/04/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $8.71 | General |
| Category: Cardiology | ||||||
| 12/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,270.00 | General |
| Category: Cardiology | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,270.00 | General |
| Category: Cardiology | ||||||
| 11/26/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $8.71 | General |
| Category: Cardiology | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: Respiratory | ||||||
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $35.71 | General |
| Category: Cardiology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $257.03 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $188.88 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $113.15 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: Respiratory | ||||||
| 11/18/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,270.00 | General |
| Category: Cardiology | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Respiratory | ||||||
| 11/15/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $28.14 | General |
| Category: Cardiology | ||||||
| 11/15/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Cardiology | ||||||
| 11/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: RESPIRATORY | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $398.11 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/13/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $20.30 | General |
| Category: HFCWO | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,916 | 3,007 | $530,558 | $259,547 |
| 2022 | 18 | 1,972 | 3,161 | $569,242 | $278,883 |
| 2021 | 19 | 2,230 | 3,687 | $647,893 | $325,503 |
| 2020 | 20 | 2,828 | 4,643 | $775,409 | $383,219 |
Total Patients
8,946
Total Services
14,498
Medicare Billing
$1.2M
Procedure Codes
79
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 272 | 792 | $109,296 | $73,868 | 67.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 309 | 567 | $92,008 | $52,158 | 56.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 114 | 294 | $110,250 | $49,271 | 44.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 114 | 120 | $32,400 | $16,078 | 49.6% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 30 | 30 | $43,350 | $14,528 | 33.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 246 | 254 | $27,432 | $10,693 | 39.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 66 | 74 | $16,845 | $10,199 | 60.5% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 18 | 18 | $25,110 | $7,675 | 30.6% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 233 | 242 | $25,168 | $7,644 | 30.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 240 | 246 | $28,044 | $7,347 | 26.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 39 | 39 | $8,265 | $4,746 | 57.4% |
| 94664 | Evaluation of use of breathing device | Office | 2023 | 174 | 260 | $7,800 | $3,242 | 41.6% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 19 | 19 | $1,558 | $887.04 | 56.9% |
| 99407 | Smoking and tobacco use intensive counseling, more than 10 minutes | Office | 2023 | 20 | 28 | $1,400 | $763.84 | 54.6% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 22 | 24 | $1,632 | $447.09 | 27.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 276 | 731 | $100,878 | $58,822 | 58.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 120 | 345 | $129,375 | $58,454 | 45.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 323 | 557 | $82,498 | $51,606 | 62.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 129 | 136 | $36,720 | $20,656 | 56.3% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2022 | 39 | 39 | $56,355 | $19,601 | 34.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 86 | 111 | $22,755 | $15,204 | 66.8% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 27 | 27 | $37,665 | $12,782 | 33.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 204 | 209 | $22,572 | $9,488 | 42.0% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2022 | 188 | 193 | $20,072 | $6,509 | 32.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 30 | 126 | $10,332 | $6,396 | 61.9% |
About Dr. Omar Minai, M.D
Dr. Omar Minai, M.D is a Pulmonary Disease healthcare provider based in Hopewell, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508820986.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Omar Minai, M.D has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $316,391 received in 2024. These payments were reported across 1,968 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.2M).
As a Medicare-enrolled provider, Minai has provided services to 8,946 Medicare beneficiaries, totaling 14,498 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Pulmonary Disease
- Location Hopewell, VA
- Active Since 04/13/2006
- Last Updated 05/13/2014
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1508820986
Products in Payments
- UPTRAVI (Drug) $388,810
- BREZTRI (Drug) $337,454
- ACTHAR (Biological) $128,223
- AREXVY (Drug) $87,072
- TRELEGY ELLIPTA (Drug) $85,477
- Adempas (Drug) $75,703
- OPSUMIT MACITENTAN (Drug) $67,607
- OFEV (Drug) $42,714
- AIRSUPRA (Drug) $23,869
- OPSUMIT (Drug) $18,575
- WINREVAIR (Biological) $12,344
- BEVESPI AEROSPHERE (Drug) $9,908
- NUCALA (Biological) $9,548
- SYMBICORT (Drug) $9,512
- UTIBRON (Drug) $8,333
- LONHALA MAGNAIR (Drug) $6,142
- Letairis (Drug) $6,091
- KEYTRUDA (Biological) $5,650
- PURIFIED CORTROPHIN GEL (Drug) $3,711
- DALIRESP (Drug) $2,800
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.